Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 12.32% and Operating profit at -4.94% over the last 5 years
2
Flat results in Mar 26
3
With ROE of 3.52%, it has a fair valuation with a 1.09 Price to Book Value
4
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
58.83%
0%
58.83%
6 Months
64.2%
0%
64.2%
1 Year
33.93%
0%
33.93%
2 Years
108.56%
0%
108.56%
3 Years
22.91%
0%
22.91%
4 Years
-18.71%
0%
-18.71%
5 Years
-72.95%
0%
-72.95%
PharmaBlock Sciences (Nanjing), Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.32%
EBIT Growth (5y)
-4.94%
EBIT to Interest (avg)
8.41
Debt to EBITDA (avg)
0.29
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
0.36
Tax Ratio
10.37%
Dividend Payout Ratio
31.82%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.44%
ROE (avg)
11.32%
Valuation key factors
Factor
Value
P/E Ratio
40
Industry P/E
Price to Book Value
1.42
EV to EBIT
36.45
EV to EBITDA
23.15
EV to Capital Employed
1.51
EV to Sales
3.42
PEG Ratio
NA
Dividend Yield
0.60%
ROCE (Latest)
4.14%
ROE (Latest)
3.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
551.40
508.00
8.54%
Operating Profit (PBDIT) excl Other Income
102.10
88.70
15.11%
Interest
0.60
0.60
Exceptional Items
2.90
1.70
70.59%
Consolidate Net Profit
50.60
48.90
3.48%
Operating Profit Margin (Excl OI)
113.70%
97.00%
1.67%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 8.54% vs -8.53% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 3.48% vs -30.44% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,962.00
1,680.80
16.73%
Operating Profit (PBDIT) excl Other Income
332.30
357.10
-6.94%
Interest
34.60
62.30
-44.46%
Exceptional Items
0.70
8.00
-91.25%
Consolidate Net Profit
183.70
219.50
-16.31%
Operating Profit Margin (Excl OI)
95.90%
129.70%
-3.38%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 16.73% vs -2.22% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -16.31% vs 11.20% in Dec 2024
About PharmaBlock Sciences (Nanjing), Inc. 
PharmaBlock Sciences (Nanjing), Inc.
Miscellaneous
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






